CompuGroup Medical’s Leadership Fully Supports CVC’s €22.00 Tender Offer, Recommends Shareholder Acceptance
(IN BRIEF) CompuGroup Medical’s governing bodies have endorsed CVC Capital Partners’ voluntary public tender offer, recommending that shareholders accept the proposed price of €22.00 per share. Following a thorough evaluation of the offer, including fairness opinions from Deutsche Bank and J.P. Morgan, the leadership expressed confidence that the partnership with CVC will support the company’s growth, particularly in cloud-based software and AI technology. The offer is subject to regulatory conditions and includes a minimum acceptance threshold of 17%. Upon completion, CVC and the Gotthardt family will hold at least 67% of the shares, with a subsequent delisting offer planned. The acceptance period for the offer runs until 23 January 2025.
(PRESS RELEASE) KOBLENZ, 03-Jan-2025 — /EuropaWire/ — CompuGroup Medical SE & Co. KGaA (ETR: COP), a leading global provider of practice management, EHR, telehealth, RCM, and laboratory software and services, announces that its Managing Directors, Administrative Board, and Supervisory Board have jointly issued a reasoned statement in response to the voluntary public tender offer from a holding company controlled by CVC Capital Partners. Following an independent review of the offer, which includes a price of €22.00 per share, the company’s governing bodies have expressed their full support for the proposal and recommended that shareholders accept the offer.
In a careful evaluation of the offer document, CompuGroup Medical’s leadership praised the strategic intentions outlined by CVC. They expressed confidence that CVC’s backing would strengthen the company’s growth trajectory, particularly its investments in cloud-based software, AI technology, and customer success. Deutsche Bank and J.P. Morgan issued fairness opinions confirming that the offer price is fair from a financial perspective.
Although Prof. Dr. Daniel Gotthardt and Frank Gotthardt, key stakeholders in the company, abstained from participating in the discussions due to their roles within the company, they have issued separate statements expressing their support for the offer.
Daniela Hommel, CFO of CompuGroup Medical, emphasized that the offer provides an immediate opportunity for shareholders to realize value with certainty. Philipp von Ilberg, Chairman of the Supervisory Board, added that the partnership aligns with CompuGroup Medical’s long-term strategy and will foster the next phase of innovation and expansion.
The offer includes a minimum acceptance threshold of 17% and is subject to regulatory conditions, such as antitrust approvals. Upon completion, CVC and the Gotthardt family are set to hold at least 67% of the shares. CVC and CompuGroup Medical also plan to take the company private, with a delisting offer expected after the tender offer’s conclusion.
The acceptance period for the offer runs from 23 December 2024 to 23 January 2025, 24:00 CET. Shareholders may tender their shares via their depositary bank.
———-
First published in this link of EuropaWIRE.
